03/06/14 04:15:21 PM
Movers: CROSS COUNTRY HEALTHCARE, INC., COPA HOLDINGS SA, THE CHILDREN''S PLACE RETAIL STORES, INC.
CROSS COUNTRY HEALTHCARE, INC.(CCRN) : CCRN posts $1.14 Q4 loss from cont. ops vs. $0.10 loss on 2.3% revenue decline. Posts $0.01 Q4 adj. loss. Capital IQ consensus forecast was $0.01 EPS. Expects Q1 revenue of $119M-$121M.
COPA HOLDINGS SA(CPA) : Citigroup downgrades CPA to neutral from buy. S&P Capital IQ maintains hold. Co. unavailable.
THE CHILDREN'S PLACE RETAIL STORES, INC.(PLCE) : PLCE posts $0.96 vs. $1.02 Q4 adj. EPS on 4.3% lower comparable retail sales, 8.2% lower net sales. Issues cautious FY 15 outlook given severe weather conditions experienced in February and early March, heightened promotional environment and an anticipated significant negative impact from foreign exchange. Sees $0.58-$0.66 Q1 adj. EPS (vs. $0.83 a year ago, $2.85-$3.05 FY 14 (vs. $3.26). Also sets $0.135 qtrly cash dividend and $100M stock buyback plan. Janney cuts ests.
STAGE STORES INC.(SSI) : SSI posts $1.01 vs. $1.15 Q4 non-GAAP EPS on 3.4% lower same-store sales, 5.4% total sales drop. Capital IQ consensus forecast was $0.99. Says it reached agreement to sell its Steele's off-price retail stores to a new retail unit of Hilco Global. Sees FY 15 same-store sales, excluding Steele's, flat to up 2%, adjusted EPS of $1.35-$1.45.
CECO ENVIRONMENTAL CORP.(CECE) : CECE posts $0.26 vs. $0.18 Q4 non-GAAP EPS on sharply higher revenue of $68.7M. Notes recent acquisitions contributed $34.3M of revenue in Q4 '13. Needham raises target, reiterates buy.
STAPLES, INC.(SPLS) : SPLS posts $0.33 vs. $0.46 Q4 non-GAAP EPS 7% lower same-store sales, 11% lower total sales. Capital IQ consensus forecast was $0.39 EPS, $5.99M revenue (vs. reported $5.87M). For Q1, expects sales to decrease y/y, EPS of $0.17-$0.22. Capital IQ consensus forecast was $0.27. Janney downgrades to neutral from buy.
REPLIGEN CORPORATION(RGEN) : RGEN posts $0.10 vs. $0.30 Q4 EPS on 18% revenue drop. Capital IQ consensus forecast was $0.14. Sees '14 revenue of $54M-$57M, incl. $2M upfront payment from BIOMARIN to be recognized during Q1 '14. Sees '14 income of $7M-$9M.
ENERGY RECOVERY, INC.(ERII) : ERII posts $0.13 Q3 EPS vs. $0.04 loss on 54% revenue rise.
CIENA CORPORATION(CIEN) : CIEN posts $0.13 vs. $0.12 Q1 non-GAAP EPS on 18% revenue rise. Capital IQ consensus forecast was $0.06. Expects Q2 revenue of $540M-$570M.
BITAUTO HOLDINGS LIMITED(BITA) : BITA posts $0.43 Q4 earnings per ADS, with 36% rise in revenue. Capital IQ consensus forecast was $0.36 normalized EPADS. Expects to generate Q1 non-GAAP EPADS of $0.14-$0.15 on revenue of $53.9M-$55.5M.
COSTCO WHOLESALE CORPORATION(COST) : COST posts $1.05 vs. $1.24 Q2 EPS despite 3% higher same-store sales (SSS), 6% higher total sales. Posts 4% higher Feb. SSS. Capital IQ consensus forecast was $1.17 Q2 EPS.
YUM! BRANDS, INC.(YUM) : Baird upgrades YUM to outperform. YUM unavailable.
SEMTECH CORPORATION(SMTC) : SMTC posts $0.23 vs. $0.49 Q4 non-GAAP EPS on 16% lower revenue. Capital IQ consensus forecast is $0.22 EPS, $125.25M revenue (vs. reported $126.53M). For Q1, expects sales to be in range $127M-$133M, GAAP EPS to be in the range of between $0.10-$0.14, non-GAAP EPS in the range of between $0.28-$0.32.
PLURISTEM THERAPEUTICS, INC.(PSTI) : PSTI says the FDA has reviewed co.'s comparability studies of its PLacental eXpanded (PLX) cell products and granted approval for co. to manufacture these products in its new commercial-scale cell manufacturing facility.
E-COMMERCE CHINA DANGDANG INC.(DANG) : DANG says Mr. Jun Zou, the chief financial officer of co., has tendered his resignation for personal reasons. His resignation will be effective on April 10, 2014.
ZUMIEZ, INC.(ZUMZ) : ZUMZ posts 2% higher February same store sales, 8.8% higher total sales.
BIOLASE, INC.(BIOL) : BIOL posts $0.04 Q4 non-GAAP loss vs. $0.05 EPS on 20% revenue drop.
RIGNET, INC.(RNET) : RNET posts $0.30 vs. $0.20 Q4 EPS on 21% revenue rise.
WUXI PHARMATECH (CAYMAN) INC.(WX) : WX posts $0.53 vs. $0.38 Q4 non-GAAP EPADS on 25% revenue rise. Sees Q1 revenues of $143M-$145M, non-GAAP EPADS of $0.36-$0.38 vs. Capital IQ consensus forecast vs. $0.40 Capital IQ consensus forecast. Sees '14 revenues of $660M-$670M, non-GAAP EPADS of $1.95-$2.00.